Tablets : 250 mg, 500 mg
Suspension : 250 mg/5ml
Injection : 500 mg
Atypical mycobacterial infections (MAI) or Mycobacterium Avium Complex (MAC) :
500 mg orally twice a day (as part of a combination regimen)
Gastrointestinal disturbances (nausea, dyspepsia, diarrhoea), rash, CNS disturbances (anxiety, headache, dizziness and confusion), taste perversion, hepatic dysfunction
Clarithromycin is an inhibitor of cytochrome P450 isoenzymes. May cause raised levels of co-administered drugs also metabolized via this route e.g. warfarin, theophylline, protease inhibitors, rifabutin. Terfenadine and astemizole contraindicated due to risk of cardiac arrhythmias. Azithromycin often used in preference.
GFR 30–50: Dose as in normal renal function
- Oral: 250–500 mg every 12–24 hours
- IV: 250-500 mg every 12 hours
- Oral: 250 mg every 12–24 hours.
- IV: 250 mg every 12 hours
Clarithromycin is both hepatically metabolized and renally excreted
There are no recommendations on dosing in patients with moderate to severe liver disease and LFTs should be monitored
Limited Human Data – Animal Data Suggest High Risk